Envoy Medical, INC. (COCHW) — SEC Filings

Overview

Envoy Medical, INC. (COCHW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Envoy Medical, Inc. reported on December 18, 2025, entering into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company, previously known as Anzu Special Acquisition Corp I, is incorporated in Delaware and operates in the or

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 7 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Envoy Medical, INC. is neutral.

Filing Type Overview

Envoy Medical, INC. (COCHW) has filed 36 8-K, 1 S-1, 3 S-1/A, 4 10-Q, 3 DEF 14A, 1 10-K, 2 SC 13G with the SEC between Apr 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Envoy Medical Enters Material Definitive Agreement — 8-K · Dec 29, 2025 Risk: medium
  Envoy Medical, Inc. reported on December 18, 2025, entering into a material definitive agreement. The filing also includes financial statements and exhibits rel
• Envoy Medical Launches 'Best Efforts' Stock, Warrant Offering — S-1 · Dec 18, 2025 Risk: high
  Envoy Medical, Inc. (COCHW) is conducting a 'reasonable best efforts' S-1 offering of Class A Common Stock and Pre-Funded Warrants, filed on December 18, 2025.
• Envoy Medical Files 8-K — 8-K · Dec 16, 2025 Risk: low
  Envoy Medical, Inc. filed an 8-K on December 16, 2025, reporting on its current activities. The filing indicates the company's principal executive offices are l
• 8-K Filing — 8-K · Dec 3, 2025
• Envoy Medical Registers 15.1M Shares for Resale Amid Rising Losses — S-1/A · Dec 1, 2025 Risk: high
  Envoy Medical, Inc. (COCHW) filed an S-1/A on December 1, 2025, primarily to register the resale of 15,116,472 shares of Class A Common Stock by selling stockho
• Envoy Medical Faces Delisting Concerns — 8-K · Nov 25, 2025 Risk: high
  Envoy Medical, Inc. filed an 8-K on November 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest
• Envoy Medical's Losses Widen Amidst Revenue Decline, Cash Dwindles — 10-Q · Nov 10, 2025 Risk: high
  Envoy Medical, Inc. (COCHW) reported a net loss of $6.482 million for the three months ended September 30, 2025, an increase from $5.960 million in the same per
• Envoy Medical Faces Delisting Concerns — 8-K · Oct 28, 2025 Risk: high
  Envoy Medical, Inc. filed an 8-K on October 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Anzu
• Envoy Medical Seeks Shareholder Nod for Warrant Issuance, Dilution Looms — DEF 14A · Oct 17, 2025 Risk: medium
  Envoy Medical, Inc. (COCHW) is seeking stockholder approval for the issuance of warrants to purchase up to 5,725,206 shares of Class A Common Stock and an addit
• Envoy Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 9, 2025 Risk: medium
  Envoy Medical, Inc. reported on October 7, 2025, entering into a material definitive agreement. The company also disclosed unregistered sales of equity securiti
• Envoy Medical Files 8-K — 8-K · Oct 7, 2025 Risk: low
  Envoy Medical, Inc. filed an 8-K on October 7, 2025, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates the company's fis
• Envoy Medical Files 8-K: Material Agreement, Equity Sales — 8-K · Sep 23, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on September 23, 2025, reporting on events as of September 22, 2025. The filing indicates the entry into a material definitive
• Envoy Medical Files 8-K with Financials — 8-K · Sep 19, 2025 Risk: low
  Envoy Medical, Inc. filed an 8-K on September 19, 2025, reporting on other events and financial statements. The company, formerly Anzu Special Acquisition Corp
• Envoy Medical Reports Material Definitive Agreement — 8-K · Sep 9, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on September 9, 2025, reporting a material definitive agreement entered into on September 4, 2025. The filing also includes fin
• Envoy Medical Faces Delisting Concerns — 8-K · Aug 29, 2025 Risk: high
  Envoy Medical, Inc. filed an 8-K on August 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of August 26,
• Envoy Medical Files 8-K: Agreement Termination & Officer Changes — 8-K · Aug 26, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on August 26, 2025, reporting the termination of a material definitive agreement and changes in its board and officer compositi
• Envoy Medical Files 8-K on Financials — 8-K · Jul 31, 2025 Risk: low
  Envoy Medical, Inc. filed an 8-K on July 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• Envoy Medical Files 8-K for Material Agreement — 8-K · Jul 29, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on July 29, 2025, reporting a material definitive agreement entered into on July 28, 2025. The filing also includes financial s
• Envoy Medical Enters Material Agreement, Reports Equity Sales — 8-K · Jul 2, 2025 Risk: medium
  Envoy Medical, Inc. entered into a material definitive agreement on June 26, 2025, related to a direct financial obligation. The company, formerly Anzu Special
• Envoy Medical Reports Director/Officer Changes & Financials — 8-K · Jun 25, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on June 25, 2025, reporting events as of June 19, 2025. The filing indicates changes related to the departure of directors or c
• Envoy Medical Files 8-K: Director Changes & Shareholder Votes — 8-K · Jun 3, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on May 28, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing
• Envoy Medical Files 8-K on Director/Officer Changes & Financials — 8-K · May 19, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on May 19, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory
• Envoy Medical Files Q1 2025 10-Q Report — 10-Q · May 1, 2025 Risk: low
  Envoy Medical, Inc. filed its quarterly report for the period ending March 31, 2025. The company, previously known as Anzu Special Acquisition Corp I, is involv
• Envoy Medical Files Proxy Statement for Annual Meeting — DEF 14A · Apr 18, 2025 Risk: low
  Envoy Medical, Inc. filed a DEF 14A proxy statement on April 18, 2025, for its annual meeting on May 28, 2025. The company, formerly Anzu Special Acquisition Co
• Envoy Medical Files 8-K on Shareholder Nominations — 8-K · Apr 11, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on April 11, 2025, reporting an event on April 10, 2025, related to shareholder nominations under Exchange Act Rule 14a-11. The
• Envoy Medical Files 8-K on Financials — 8-K · Mar 31, 2025 Risk: low
  Envoy Medical, Inc. filed an 8-K report on March 31, 2025, detailing its financial condition and results of operations. The filing includes financial statements
• Envoy Medical Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Envoy Medical, Inc. filed its 2024 10-K report, detailing its operations in orthopedic, prosthetic, and surgical appliances. The company, formerly Anzu Special
• Envoy Medical Reports Definitive Agreement and Equity Sales — 8-K · Mar 12, 2025 Risk: medium
  Envoy Medical, Inc. entered into a material definitive agreement on March 6, 2025, related to the creation of a direct financial obligation. The company also re
• Envoy Medical Faces Delisting Concerns — 8-K · Mar 3, 2025 Risk: high
  Envoy Medical, Inc. filed an 8-K on February 25, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Anz
• Envoy Medical Files 8-K for Material Agreement — 8-K · Jan 21, 2025 Risk: medium
  Envoy Medical, Inc. filed an 8-K on January 21, 2025, reporting a material definitive agreement entered into on January 17, 2025. The filing also includes finan
• Envoy Medical Signs Material Definitive Agreement — 8-K · Dec 23, 2024 Risk: medium
  Envoy Medical, Inc. entered into a Material Definitive Agreement on December 19, 2024. The filing also includes financial statements and exhibits related to thi
• Envoy Medical Files 8-K with Material Agreements — 8-K · Dec 20, 2024 Risk: medium
  Envoy Medical, Inc. filed an 8-K on December 20, 2024, reporting a material definitive agreement. The filing also covers modifications to security holder rights
• Envoy Medical Files 8-K: Material Agreement & Financials — 8-K · Dec 17, 2024 Risk: medium
  Envoy Medical, Inc. entered into a material definitive agreement on December 11, 2024, which also created a direct financial obligation for the registrant. The
• Envoy Medical Holds Shareholder Meeting — 8-K · Nov 20, 2024 Risk: low
  Envoy Medical, Inc. filed an 8-K on November 20, 2024, reporting a shareholder meeting held on November 14, 2024. The primary purpose of the meeting was for sec
• SC 13G Filing — SC 13G · Nov 14, 2024
• Envoy Medical Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: low
  Envoy Medical, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, previously known as Anzu Special Acquisition Corp I, is invol
• SC 13G Filing — SC 13G · Nov 13, 2024
• Envoy Medical Files Definitive Proxy Statement — DEF 14A · Oct 4, 2024 Risk: low
  Envoy Medical, Inc. filed a definitive proxy statement (DEF 14A) on October 4, 2024, for its fiscal year ending December 31, 2024. The filing pertains to the co
• Envoy Medical Files 8-K on Shareholder Nominations — 8-K · Sep 6, 2024 Risk: low
  Envoy Medical, Inc. filed an 8-K on September 6, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing does not contain sp
• Envoy Medical Files 8-K with Material Agreement — 8-K · Aug 28, 2024 Risk: medium
  Envoy Medical, Inc. filed an 8-K on August 28, 2024, reporting on events that occurred on August 27, 2024. The filing indicates a material definitive agreement
• Envoy Medical Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: low
  Envoy Medical, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, previously known as Anzu Special Acquisition Corp I, is involved i
• Envoy Medical Files 8-K: Material Agreement & Financials — 8-K · Aug 1, 2024 Risk: medium
  Envoy Medical, Inc. entered into a Material Definitive Agreement on July 29, 2024. The filing also includes financial statements and exhibits. The company, form
• Envoy Medical Files 8-K on Agreements and Equity Sales — 8-K · Jul 25, 2024 Risk: medium
  Envoy Medical, Inc. entered into a Material Definitive Agreement on July 22, 2024, related to the creation of a direct financial obligation. The company also re
• Envoy Medical Files 8-K with Financial Updates — 8-K · Jul 15, 2024 Risk: low
  Envoy Medical, Inc. filed an 8-K on July 15, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates the compa
• Envoy Medical Enters Material Definitive Agreement — 8-K · Jun 25, 2024 Risk: medium
  Envoy Medical, Inc. announced on June 24, 2024, that it entered into a Material Definitive Agreement. The filing does not specify the other party or the terms o
• Envoy Medical Reports Director/Officer Changes & Compensatory Info — 8-K · Jun 11, 2024 Risk: medium
  Envoy Medical, Inc. filed an 8-K on June 11, 2024, reporting events as of June 6, 2024. The filing includes information regarding the departure of directors or
• Envoy Medical Reports Material Agreement and Equity Sales — 8-K · May 24, 2024 Risk: medium
  On May 23, 2024, Envoy Medical, Inc. entered into a material definitive agreement related to the creation of a direct financial obligation. The company also rep
• Envoy Medical Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  Envoy Medical, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and e
• Envoy Medical, Inc. Files Amendment No. 3 to S-1 Registration Statement — S-1/A · Apr 25, 2024 Risk: low
  Envoy Medical, Inc. (COCHW) filed a Amended IPO Registration (S-1/A) with the SEC on April 25, 2024. Envoy Medical, Inc. filed Amendment No. 3 to its Form S-1 R
• Envoy Medical, Inc. Files Amendment No. 2 to S-1 Registration Statement — S-1/A · Apr 5, 2024 Risk: low
  Envoy Medical, Inc. (COCHW) filed a Amended IPO Registration (S-1/A) with the SEC on April 5, 2024. Envoy Medical, Inc. filed an amendment (No. 2) to its S-1 Re

Risk Profile

Risk Assessment: Of COCHW's 47 recent filings, 7 were flagged as high-risk, 24 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Envoy Medical, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $166K
• Net Income: -$17.170M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $3.556M
• Operating Margin: N/A
• Total Assets: $8.181M
• Total Debt: $0

Key Executives

• Brent T. Lucas
• Andrew Nick
• Edward Peilen
• Brent Lucas
• David P. Slotkin
• Andrew P. Campbell

Industry Context

Envoy Medical operates in the hearing health industry, specifically focusing on implantable medical devices for hearing loss. The cochlear implant market, where the Acclaim CI is positioned, is established but faces competition from existing technologies and manufacturers. The company aims to differentiate through its fully implanted sensor technology, which leverages natural ear anatomy rather than external microphones.

Top Tags

material-agreement (9) · material-definitive-agreement (7) · equity-sale (6) · 8-k (6) · financial-reporting (6) · corporate-governance (6) · corporate-action (5) · Medical Devices (4) · filing (4) · delisting (4)

Key Numbers

• Common Stock Price: $0.703 — Last reported sale price on Nasdaq as of December 17, 2025, indicating current market valuation.
• Pre-Funded Warrant Exercise Price: $0.0001 — The nominal exercise price for each Pre-Funded Warrant, highlighting the pre-funded nature.
• Beneficial Ownership Threshold: 4.99% — Threshold for investors to receive Pre-Funded Warrants instead of Common Stock, to avoid exceeding beneficial ownership limits.
• Beneficial Ownership Threshold (Investor Election): 9.99% — Alternative beneficial ownership threshold for investors electing to receive Pre-Funded Warrants.
• Shares registered for resale: $15.1M — Total shares from warrant exercises that could enter the market
• Net loss for Q3 2025: $6.5M — Increased from $6.0 million in Q3 2024, indicating growing operational losses
• Net loss for 9 months ended Sep 30, 2025: $17.2M — Increased from $16.2 million for the same period in 2024, showing accelerating losses
• Accumulated deficit as of Sep 30, 2025: $305.7M — Significant increase from $284.7 million at Dec 31, 2024, highlighting substantial historical losses
• September Private Placement Warrant exercise price: $1.31 — Exercise price for 5,725,206 shares
• October Private Placement Warrant exercise price: $1.33 — Exercise price for 9,022,572 shares
• COCH stock price on Nov 21, 2025: $0.72 — Last reported sale price, significantly below warrant exercise prices
• Anticipated FDA decision for Acclaim CI: 2027-2028 — Timeline for potential regulatory approval, indicating long lead time to market
• Total patients in Acclaim CI clinical trial: 56 — Number of patients planned for the pivotal clinical study
• Patients in Stage 1 of Acclaim CI clinical trial: 10 — Initial group of patients successfully implanted and activated
• Cash: $3.556M — Decreased from $5.483M at Dec 31, 2024, indicating significant cash burn.

Related Companies

COCH · EMED

Frequently Asked Questions